MauritiusTuberculosis profile
Population  2015 1.3 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.019 (0.019–0.019) 1.5 (1.5–1.5)
Mortality (HIV+TB only) 0.013 (<0.01–0.021) 1 (0.55–1.6)
Incidence  (includes HIV+TB) 0.28 (0.18–0.39) 22 (14–31)
Incidence (HIV+TB only) 0.035 (0.022–0.05) 2.7 (1.7–3.9)
Incidence (MDR/RR-TB)** <0.01 (0–0.012) 0.39 (0–0.94)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.021 (0.017–0.025) 0.086 (0.032–0.14) 0.11 (0.049–0.17)
Males 0 (0–0) 0.17 (0.12–0.22) 0.17 (0.12–0.22)
Total 0.021 (0.013–0.029) 0.26 (0.2–0.31) 0.28 (0.18–0.39)
TB case notifications, 2015  
Total cases notified 129
Total new and relapse 128
          - % tested with rapid diagnostics at time of diagnosis 95%
          - % with known HIV status 97%
          - % pulmonary 95%
          - % bacteriologically confirmed among pulmonary 100%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 46% (32–72)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.12 (0.08–0.19)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 14 11%
          - on antiretroviral therapy 14 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  2
(0–5)
Estimated % of TB cases with MDR/RR-TB 1.7% (0.2–5.9) 0% (0–71)  
% notified tested for rifampicin resistance 94% 100% 122
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 2, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 2, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 90% 126
Previously treated cases, excluding relapse, registered in 2014 100% 1
HIV-positive TB cases, all types, registered in 2014 60% 15
MDR/RR-TB cases started on second-line treatment in 2013   0
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment <1%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data